MYGNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31

MYRIAD GENETICS INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026

$4.21+0.23 (+5.78%)

Close on Oct 19, 2026

Community

Notes and questions about Myriad Genetics from other investors

Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Parsed from the XBRL in Myriad Genetics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 2-for-1 split on Mar 26, 2009
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is MYGN.

Revenue growth-3.2% · median -1.4%

Gross margin68.8% · median 46.0%

Operating margin-12.2% · median -4.5%

Net margin-14.0% · median -9.4%

Advertisement
300 × 250